John Fanikos Shares Greg Piazza’s Presentation On The Results of The HI-Pro Trial
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared on LinkedIn:
”The best part of my pharmacist career was spending time with the Thrombosis Research Group.
Dr. Greg Piazza presented the results of the HI-Pro Trial at the European Society Meeting over the Labor Day weekend in Madrid, Spain.
There are often reasons (surgery, infection, injury) patients developed blood clots (deep vein thrombosis and pulmonary embolism) in their legs and lungs.
These events were called “provoked” and treated with medicines (anticoagulants) for 3-6 months.
Dr. Piazza’s research suggests treating longer, and with a lower dose, may prevent repeat events and be better for patients.
Kudos to the research group. Kudos to the Investigational Drug Service Pharmacy (IDS) that delivered the drugs by foot, by FedEx, and by UPS in the peri-pandemic period to keep patients on their medications.
I was honored to be included.”
Stay updated on the latest news in the field of thrombosis with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!